Eflornithine and / or Sulindac in Preventing Recurrence of High-Risk Adenomas and Second Primary Disease in Patients with Stage 0-III Colon or Rectal Cancer
Inclusion Criteria
- STEP 0: REGISTRATION (Optional)
- Patients with a primary colon or rectal cancer resection who are potentially eligible for S0820 may be pre-registered at Step 0; patients registered to Step 0 will appear on an institutional patient tracking report; patients registered to Step 0 are not registered to the S0820 protocol; to participate in S0820, patients must be registered to Step 1 after patient is consented and evaluation of eligibility; patients registered to S0820 at Step 0 continuing to Step 1 registration must use the same Southwest Oncology Group (SWOG) patient identification (ID) for registration to S0820 Step 1
- STEP 1: REGISTRATION
- Patients must have a history of stage 0, I, II or III colon or rectal adenocarcinoma that has been treated per standard care with resection alone or in combination with radiation or chemotherapy; adjuvant chemotherapy and radiation therapy (RT) treatment must have been completed at least 30 days prior to registration
- Patients with history of segmental resections are eligible (i.e. right colectomy, extended right colectomy, transverse colectomy, left colectomy, extended left colectomy, sigmoid colectomy, low anterior resection, abdominoperineal resection); the definition of resection does not include endomucosal resection (EMR); patients that have received total proctocolectomy are ineligible * In addition to segmental resections, the following types of procedures are allowed: polypectomy: for Tis (stage 0) or pT1 patients only, resection may consist entirely of polypectomy (without completion of partial colectomy) if ALL of the following criteria are met: ** Single specimen, completely removed ** Negative margins of resection ** Grade 1 or 2 ** No angiolymphatic invasion * Transanal excision is allowed for pT1 rectal cancer patients with well or moderately differentiated tumors if National Comprehensive Cancer Network (NCCN) criteria for transanal excision are met, as stipulated here: ** NCCN Criteria for Transanal excision: *** < 3 cm in size *** T1 *** Grade 1 or 2 *** No lymphatic or venous invasion *** Negative margin *** Sm3 depth of tumor invasion is not allowed * When the lesion can be adequately identified in the rectum, transanal endoscopic microsurgery (TEM) may be used; TEM for more proximal lesions may be technically feasible
- Patients must be registered between 120 days and 456 days (inclusive) of primary resection; patients must show no evidence of colorectal cancer based on post-operative colonoscopy (performed at least 120 days after the colon or rectal resection date and prior to registration); patients with adenomas detected at the one-year postoperative colonoscopy are eligible if all adenomas have been completely removed
- Patients must have a pure tone audiometry evaluation to document air conduction within 30 days prior to registration; patients with hearing loss > 40 decibels (dB) in any of the five tested frequencies (250 Hertz [Hz], 500 Hz, 1,000 Hz, 2,000 Hz, 4,000 Hz) are not eligible; patients with active ear infections should be tested only after the acute phase of infection has resolved; for optimal results, it is recommended that testing be conducted by an audiologist, in a hearing test room, with insert earphones; Note: sites should not order audiometry evaluation until the potential participant has met all other eligibility criteria required for this study
- Patients must have a Zubrod performance status of 0-1
- Patients must have the ability to swallow oral medication
- Total white blood cells (WBC) >= 4.0 x 10^3/mcL (within 28 days prior to registration)
- Platelets >= 100,000/mcL (within 28 days prior to registration)
- Hemoglobin > 11.0 g/dL (within 28 days prior to registration)
- A total WBC >= 3.1 x 10^3/mcL is allowed for non-Hispanic black males (NHBM) and total WBC >= 3.4 x 10^3/mcL for non-Hispanic black females (NHBF) * Exception: If the WBC is lower than the above levels, the patient may be enrolled IF the absolute neutrophil count (ANC) is >= 1.3 for NHBM, >= 1.4 for NHBF, or >= 1.5 for all
- Serum bilirubin =< 2.0 mg/dL (within 28 days prior to registration)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) or alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2 x IULN (institutional upper limit of normal) (within 28 days prior to registration)
- Serum creatinine =< 1.5 x IULN obtained within 28 days prior to registration
- Patients with a prior malignancy or concurrent malignancy that is currently not being treated, whose natural history or treatment (in the opinion of the treating physician) does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen, are eligible for this trial
- SPECIMEN SUBMISSION AND SUBSTUDY CRITERIA
- Patients must be offered the option to participate in submission of specimens for banking for future translational medicine studies
- Patients participating through PK sites, must be offered the option to submit blood specimens for population pharmacokinetic analysis
- Patients must be offered the option to participate in the Diet and Lifestyle Substudy
- REGULATORY CRITERIA
- All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
- As part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
Exclusion Criteria
- Patients must not have cardiovascular risk factors including unstable angina, history of documented myocardial infarction or cerebrovascular accident, coronary artery bypass surgery, or New York Heart Association class III or IV heart failure; patients must not have known uncontrolled hyperlipidemia (defined as low-density lipoprotein cholesterol [LDL-C] >= 190 mg/dL or triglycerides >= 500 mg/dL) within the last 3 years prior to registration or uncontrolled high blood pressure (systolic blood pressure > 150 mm Hg) within 28 days prior to registration
- Patients must not have a known history of familial adenomatous polyposis, hereditary nonpolyposis colorectal cancer, inflammatory bowel disease, biallelic mismatch repair deficiency syndrome (BMMRD), or constitutional mismatch repair deficiency syndrome (CMMRD)
- Patients must not have known hypersensitivity to eflornithine or sulindac or the excipients byproducts; patients must not have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other non-steroidal antiinflammatory drug (NSAID)
- Patients must not have documented history of gastric/duodenal ulcer within the last 12 months; participant must not currently be on treatment for gastric/duodenal ulcer or be experiencing symptoms at study entry; patients with gastroesophageal reflux disease (GERD) are eligible, however, and these patients may receive over-the-counter histamine-2 (H2) antagonists; proton-pump inhibitors, or other prescription-based treatment for GERD
- Patients must not be expecting to receive radiation or additional chemotherapy
- Patients must not be receiving or plan to receive concomitant oral or intravenous corticosteroids on a regular basis, nonsteroidal anti-inflammatory drugs (NSAIDs), nor anticoagulants on a regular or predictable intermittent basis; (NSAID use may not exceed 10 days per month); patients may receive daily aspirin for cardiovascular prophylaxis as long as acetylsalicylic acid (ASA) is =< 100 mg per day or =< two 325 mg tablets per week; inhaled steroids (i.e. for asthma or related conditions) are allowed
- Patients must have no significant medical or psychiatric condition that would preclude study completion; tests and exams for this determination should be completed within 28 days prior to registration
- Patients must not be pregnant or nursing (due to the status of eflornithine and sulindac as pregnancy class C agents); women/men of reproductive potential must have agreed to use an effective contraceptive method; a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures
- Individuals must not currently be participating in any other clinical trial for the treatment or prevention of cancer unless they are no longer receiving the intervention and are in the follow-up phase only; patients must also agree not to join such a trial while participating in this study
Alabama
Birmingham
Alaska
Anchorage
Fairbanks
Arizona
Gilbert
Phoenix
Tucson
Arkansas
Hot Springs
Jonesboro
Little Rock
Rogers
California
Anaheim
Antioch
Arroyo Grande
Auburn
Baldwin Park
Bellflower
Berkeley
Burbank
Burlingame
Cameron Park
Castro Valley
Chico
Clovis
Costa Mesa
Davis
Duarte
Dublin
Emeryville
Fontana
Fremont
Fresno
Harbor City
Irvine
La Jolla
Loma Linda
Los Angeles
Martinez
Modesto
Mountain View
Novato
Oakland
Ontario
Orange
Palo Alto
Panorama City
Pasadena
Pleasant Hill
Pleasanton
Rancho Mirage
Redwood City
Richmond
Riverside
Roseville
Sacramento
San Diego
San Francisco
San Jose
San Leandro
San Luis Obispo
San Marcos
San Pablo
San Rafael
Santa Clara
Santa Cruz
Santa Maria
Santa Rosa
South San Francisco
Stockton
Sunnyvale
Vacaville
Vallejo
Walnut Creek
Whittier
Woodland Hills
Colorado
Aurora
Boulder
Colorado Springs
Denver
Durango
Englewood
Fort Collins
Golden
Greeley
Greenwood Village
Lakewood
Littleton
Lone Tree
Longmont
Loveland
Parker
Pueblo
Thornton
Wheat Ridge
Connecticut
Bridgeport
Derby
Fairfield
Greenwich
Guilford
Hartford
Middletown
New Haven
North Haven
Orange
Stamford
Torrington
Trumbull
Waterbury
Waterford
West Haven
Delaware
Lewes
Newark
Rehoboth Beach
Seaford
Wilmington
District of Columbia
Washington
Florida
Miami
Plant City
Saint Petersburg
Tampa
Georgia
Albany
Atlanta
Columbus
Fort Gordon
Gainesville
Savannah
Hawaii
Aiea
Honolulu
Kailua
Lihue
Wailuku
Idaho
Boise
Caldwell
Coeur D'Alene
Emmett
Fruitland
Lewiston
Meridian
Nampa
Post Falls
Sandpoint
Twin Falls
Illinois
Aurora
Berwyn
Bloomington
Canton
Carbondale
Carterville
Carthage
Centralia
Chicago
Danville
Decatur
Effingham
Eureka
Galesburg
Geneva
Harvey
Hines
Kewanee
Macomb
Mattoon
Maywood
Monmouth
Mount Vernon
Normal
O'Fallon
Oak Lawn
Ottawa
Pekin
Peoria
Peru
Princeton
River Forest
Rockford
Springfield
Swansea
Urbana
Warrenville
Yorkville
Indiana
Crown Point
Elkhart
Indianapolis
Kokomo
La Porte
Merrillville
Michigan City
Mishawaka
Plymouth
Richmond
South Bend
Valparaiso
Westville
Iowa
Bettendorf
Cedar Rapids
Clive
Council Bluffs
Creston
Des Moines
Iowa City
Mason City
Sioux City
Waterloo
West Des Moines
Kansas
Chanute
Dodge City
El Dorado
Emporia
Fort Scott
Garden City
Great Bend
Hays
Hutchinson
Independence
Kansas City
Kingman
Lawrence
Lenexa
Liberal
Manhattan
McPherson
Newton
Olathe
Overland Park
Parsons
Pittsburg
Pratt
Salina
Topeka
Wellington
Wichita
Winfield
Kentucky
Bardstown
Corbin
Crestview Hills
Edgewood
Fort Thomas
Lexington
London
Louisville
Morehead
Shepherdsville
Louisiana
Baton Rouge
Houma
Independence
Kenner
Metairie
Monroe
New Orleans
Shreveport
Maine
Lewiston
Maryland
Baltimore
Bel Air
Cumberland
Elkton
Gaithersburg
Largo
Olney
Massachusetts
Beverly
Brighton
Gloucester
Jamaica Plain
Springfield
Michigan
Adrian
Ann Arbor
Battle Creek
Bay City
Big Rapids
Brighton
Canton
Caro
Chelsea
Clarkston
Dearborn
Detroit
East China
Escanaba
Farmington Hills
Flint
Grand Rapids
Grosse Pointe Woods
Iron Mountain
Jackson
Kalamazoo
Lansing
Lapeer
Livonia
Macomb Township
Marlette
Monroe
Mount Clemens
Mount Pleasant
Muskegon
Niles
Petoskey
Pontiac
Port Huron
Reed City
Rochester Hills
Royal Oak
Saginaw
Saint Joseph
Southfield
Sterling Heights
Tawas City
Traverse City
Troy
Warren
West Branch
Wyoming
Ypsilanti
Minnesota
Aitkin
Bemidji
Brainerd
Burnsville
Coon Rapids
Deer River
Duluth
Edina
Fergus Falls
Fridley
Hibbing
Hutchinson
Maple Grove
Maplewood
Minneapolis
New Ulm
Robbinsdale
Rochester
Saint Cloud
Saint Louis Park
Saint Paul
Sandstone
Shakopee
Stillwater
Virginia
Waconia
Willmar
Woodbury
Wyoming
Mississippi
Corinth
Grenada
Jackson
New Albany
Oxford
Pascagoula
Southaven
Southhaven
Missouri
Bonne Terre
Cape Girardeau
Independence
Jefferson City
Joplin
Kansas City
Lee's Summit
Liberty
Saint Joseph
Saint Louis
Sainte Genevieve
Springfield
Sullivan
Sunset Hills
Montana
Anaconda
Billings
Bozeman
Butte
Great Falls
Helena
Kalispell
Missoula
Nebraska
Grand Island
Kearney
Lincoln
Norfolk
North Platte
Omaha
Papillion
Scottsbluff
Nevada
Henderson
Las Vegas
New Hampshire
Concord
Exeter
Laconia
Manchester
New Jersey
Camden
Morristown
Mount Holly
Mullica Hill
Pompton
Summit
Toms River
Vineland
Voorhees
New Mexico
Albuquerque
Rio Rancho
Santa Fe
New York
Auburn
East Syracuse
Elmira
Glens Falls
Lake Success
Liverpool
New York
Rochester
Rome
Stony Brook
Syracuse
White Plains
North Carolina
Belmont
Charlotte
Clinton
Gastonia
Goldsboro
Hendersonville
Huntersville
Jacksonville
Matthews
Mooresville
Shelby
North Dakota
Bismarck
Fargo
Grand Forks
Minot
Ohio
Beachwood
Beavercreek
Belpre
Bowling Green
Canton
Centerville
Chardon
Chillicothe
Cincinnati
Cleveland
Columbus
Dayton
Delaware
Dublin
Elyria
Fairfield
Findlay
Franklin
Gahanna
Greenville
Grove City
Independence
Kettering
Lancaster
Lima
Mansfield
Marietta
Marion
Maumee
Mayfield Heights
Mentor
Middleburg Heights
Middletown
Mount Vernon
Newark
Oregon
Parma
Portsmouth
Sandusky
Sidney
Springfield
Strongsville
Sylvania
Tiffin
Toledo
Troy
WPAFB
Warrensville Heights
Wauseon
Westerville
Westlake
Wooster
Xenia
Zanesville
Oklahoma
Lawton
Oklahoma City
Oregon
Baker City
Bend
Clackamas
Coos Bay
Newberg
Ontario
Oregon City
Portland
Pennsylvania
Abington
Allentown
Bethlehem
Bryn Mawr
Collegeville
Danville
East Stroudsburg
Easton
Exton
Hazleton
Lewisburg
Lewistown
Media
Paoli
Phoenixville
Pottsville
Scranton
Selinsgrove
State College
West Chester
West Reading
Wilkes-Barre
Willow Grove
Wynnewood
South Carolina
Anderson
Beaufort
Boiling Springs
Charleston
Easley
Gaffney
Greenville
Greenwood
Greer
Mount Pleasant
Seneca
Spartanburg
Union
South Dakota
Sioux Falls
Tennessee
Chattanooga
Collierville
Germantown
Hixson
Knoxville
Memphis
Nashville
Ooltewah
Texas
Abilene
Bryan
Dallas
Fort Sam Houston
Houston
Lubbock
San Antonio
Temple
Vermont
Berlin
Burlington
White River Junction
Virginia
Burke
Fredericksburg
Martinsville
McLean
Washington
Aberdeen
Anacortes
Auburn
Bainbridge Island
Bellevue
Bellingham
Bremerton
Burien
Centralia
Edmonds
Enumclaw
Everett
Federal Way
Gig Harbor
Issaquah
Kennewick
Kirkland
Lacey
Lakewood
Longview
Lynnwood
Mount Vernon
Olympia
Port Townsend
Poulsbo
Puyallup
Renton
Seattle
Sedro-Woolley
Shelton
Spokane
Spokane Valley
Tacoma
Vancouver
Walla Walla
Wenatchee
Yakima
Yelm
West Virginia
Huntington
Princeton
Wisconsin
Antigo
Ashland
Chippewa Falls
Eau Claire
Green Bay
La Crosse
Manitowoc
Marinette
Marshfield
Medford
Minocqua
New Richmond
Oconto Falls
Rhinelander
Rice Lake
Sheboygan
Stevens Point
Sturgeon Bay
Wausau
Weston
Wisconsin Rapids
Wyoming
Casper
Cheyenne
Cody
Sheridan
PRIMARY OBJECTIVE:
I. To assess whether the combination of eflornithine and sulindac is effective in reducing the three-year event rate (high-risk adenomas and second primary colorectal cancers) in patients with previously treated stage 0-III colon or rectal cancer.
SECONDARY OBJECTIVES:
I. To assess whether the combination of eflornithine and sulindac (compared to corresponding placebos) has efficacy against colorectal lesions with respect to high-grade dysplasia, adenomas with villous features, adenomas 1 cm or greater, multiple adenomas, any adenomas >= 0.3 cm, total advanced colorectal events, or total colorectal events.
II. To assess quantitative and qualitative toxicities of patients when treated with the combination of eflornithine and sulindac compared to corresponding placebos.
III. To evaluate a minimal set of tagging single nucleotide polymorphisms across multiple genes relevant to eflornithine and sulindac, in order to characterize associations with decreased adenoma/second primary colorectal cancer (CRC) risk and adverse events.
IV. To evaluate biomarker responses of treatment effect using novel microfluidics-based digital droplet detection system.
V. To explore the interaction of intervention arm and baseline statin use with respect to the 3-year event rate.
VI. To explore the interaction of the intervention arm and patient-reported meat consumption with respect to the 3-year event rate.
VII. To perform population pharmacokinetic (PK) analysis of eflornithine and sulindac in patients with previously treated stage 0-III colon or rectal cancer.
OUTLINE: Patients are randomized to 1 of 4 arms.
ARM I: Patients receive eflornithine placebo orally (PO) once daily (QD) and sulindac placebo PO QD for 36 months in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive eflornithine PO QD and sulindac placebo PO QD for 36 months in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL PER PROTOCOL DATED 01/27/17)
ARM III: Patients receive eflornithine placebo PO QD and sulindac PO QD for 36 months in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL PER PROTOCOL DATED 01/27/17)
ARM IV: Patients receive eflornithine PO QD and sulindac PO QD for 36 months in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up annually for 5 years.
Trial Phase Phase III
Trial Type Prevention
Lead Organization
SWOG
Principal Investigator
Jason Adam Zell
- Primary ID S0820
- Secondary IDs NCI-2012-02067, SWOG-S0820, s17-00109
- Clinicaltrials.gov ID NCT01349881